As the Democratic Republic of the Congo faces the fastest-growing Ebola outbreak on record, caused by the Bundibugyo virus (BDBV), GeoVax Labs, Inc. (Nasdaq: GOVX) is highlighting its vaccine development capabilities that could be relevant to the crisis. The outbreak, which has already reported over 4,300 cases and 2,000 deaths, is on a trajectory that may exceed the toll of the 2014-2016 West Africa epidemic, according to the World Health Organization (WHO). With no approved vaccine specifically for Bundibugyo virus, GeoVax is offering its expertise and MVA-based vaccine candidates to support global response efforts.
GeoVax's MVA platform has been used to develop vaccine candidates against Zaire ebolavirus, Sudan ebolavirus, and Marburg virus, all of which have shown protective efficacy in non-human primate lethal-challenge studies. The company is prepared to engage with WHO, Africa CDC, and national health authorities to determine how its candidates, technology, or scientific expertise could contribute to the response. David Dodd, CEO of GeoVax, emphasized the importance of having vaccine technologies ready before a crisis, stating, "We are prepared to engage... to determine whether our vaccine candidates, technology or scientific expertise could contribute to the response."
GeoVax's lead infectious disease program, GEO-MVA, is an MVA-based vaccine for mpox and smallpox, which is advancing toward pivotal clinical trials through an immunobridging pathway. Portions of these trials are expected to be conducted in African regions, including areas affected by the Ebola outbreak. The company has already been building relationships with healthcare and research organizations in the region, which could facilitate collaboration on Ebola response. Dodd noted, "Our relationships in the region are being developed first and foremost to advance GEO-MVA, but many of the organizations with whom we are engaging are simultaneously confronting this Ebola outbreak."
Beyond GEO-MVA, GeoVax retains a portfolio of hemorrhagic fever vaccine candidates that could offer strategic optionality. The company is open to collaborations, licensing, and public-private partnerships that could further develop these assets without diverting resources from GEO-MVA. "GeoVax believes its combination of MVA platform expertise, hemorrhagic fever vaccine candidates and work to advance scalable MVA manufacturing provides a foundation for potential collaborations addressing Ebola and other emerging infectious disease threats," the company stated.
The urgency of the outbreak underscores the need for preparedness and collaboration. GeoVax's willingness to contribute its scientific expertise and candidates highlights the potential role of biotechnology companies in global health emergencies. As the situation evolves, the company remains focused on its primary mission while exploring ways to assist in the response.
